Brooks Laboratories Limited focuses on critical care products including Beta Lactam, Cephalosporin, and General Dry powder Injectables. It provides a diverse product portfolio for multiple companies.

Brooks Laboratories major competitors are Fredun Pharma, Albert David, Medicamen Biotech, Zim Laboratories, Lyka Labs, Jenburkt Pharma, Trident Lifeline.
Market Cap of Brooks Laboratories is ₹465 Crs.
While the median market cap of its peers are ₹498 Crs.

Brooks Laboratories seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.